Mainz Biomed B.V. (MYNZ)
NASDAQ: MYNZ · IEX Real-Time Price · USD
0.857
-0.040 (-4.48%)
At close: Apr 25, 2024, 4:00 PM
0.823
-0.034 (-3.94%)
Pre-market: Apr 26, 2024, 5:24 AM EDT
Company Description
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics.
It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test.
The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases.
The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed B.V.
Country | Germany |
Founded | 2021 |
IPO Date | Nov 5, 2021 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 65 |
CEO | Guido Baechler |
Contact Details
Address: Robert Koch Strasse 50 Mainz, 2M 55129 Germany | |
Phone | 49 6131 5542860 |
Website | mainzbiomed.com |
Stock Details
Ticker Symbol | MYNZ |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001874252 |
CUSIP Number | N5436L101 |
ISIN Number | NL0015000LC2 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Guido Baechler | Chief Executive Officer and Executive Director |
William J. Caragol | Chief Financial Officer |
Dr. Christopher Von Torne P.M.P., Ph.D. | Chief Operating Officer |
Dr. Frank Krieg-Schneider | Chief Technology Officer |
Dr. Moritz Eidens Ph.D. | Chief Science Officer and Executive Director |
Stefan Erlach | Head of Human Resources |
Philipp Freese | Chief Business Officer |
Darin S. Leigh | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 24, 2024 | 6-K | Report of foreign issuer |
Apr 19, 2024 | 6-K | Report of foreign issuer |
Apr 9, 2024 | 20-F | Annual and transition report of foreign private issuers |
Feb 23, 2024 | 6-K | Report of foreign issuer |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 16, 2023 | 6-K | Report of foreign issuer |
Nov 15, 2023 | 6-K | Report of foreign issuer |
Nov 14, 2023 | 424B5 | Filing |
Nov 13, 2023 | 6-K | Report of foreign issuer |
Sep 26, 2023 | 424B5 | Filing |